Rare Hemophilia Factors Market Is Expected To Reach US$ 520 Million By 2032

The global rare hemophilia factors market is valued at US$ 290 million in 2022 and is forecasted to expand at 6% CAGR through 2032.

A major issue for the healthcare industry is the growing prevalence of uncommon illnesses among people worldwide. One of the rarest bleeding conditions, hemophilia, is characterized by insufficient clotting factors in the blood. Because the hemophilia gene is defective, hemophilia patients typically bleed unnaturally and for a longer period than healthy individuals. Around 70% of hemophilia cases are hereditary and are typically brought on by gene mutation.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.factmr.com/connectus/sample?flag=S&rep_id=7801?PS

Hemophilia patients can lead healthy lives if they receive proper and successful therapy. The patient receives an injection of the missing clotting factors to stop the abnormal bleeding. The population's growing knowledge of such rare diseases and government involvement in their prevention and control are elements driving market value growth. The overall demand for rare hemophilia factors is predicted to increase during the forecast period due to the rapidly growing global hemophilia patient pool and improvements in hemophilia treatment methods.

One of the major trends for rare hemophilia that is anticipated to have a beneficial impact on market expansion over the coming years is the advent of gene therapy. Delivering stable insertion and expression of a gene, whose absence causes hemophilia A or B, is the goal of gene therapy for hemophilia.

The market is also expanding due to many other variables, such as the rising adoption and approval of innovative treatment modalities and an increase in the number of government programs.

𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬 𝐟𝐫𝐨𝐦 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐭𝐮𝐝𝐲

• Market in Canada is forecasted to expand at a CAGR of 5.3% over the forecast period.
• The global rare hemophilia factors market is predicted to reach US$ 520 million by 2032.
• Market in Japan is anticipated to progress at a CAGR of 5.7% through 2032.
• Demand for factor concentrates is estimated to rise at a CAGR of 5.8% By 2032.
• Competitive Landscape

Several key companies are embracing techniques, including strategic partnerships and marketing to boost the awareness of novel techniques.

For instance :

In 2020, to prevent and treat bleeding in people with hemophilia A, Novo Nordisk announced the release of ESPEROCT, a long-acting recombinant factor VIII medication. This novel medicine is specifically recommended for routine prophylaxis to lessen the incidence of major bleeding, provide on-demand treatment, and manage bleeding during surgery.

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7801?PS

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬

Amgen Inc.
BioMarin
Bio Products Laboratory Ltd.
Biogen Inc.
CSL Behring
Baxter International Inc.
Bayer AG
Novo Nordisk A/S
Pfizer, Inc.
Takeda Pharmaceutical Co. Ltd.
Alexion Pharmaceuticals, Inc.
Shire plc
ICON plc
Winning Strategy

Top market players are focused on introducing innovative therapies for hemophilia that are both effective and affordable.

For instance,

In 2022, with the introduction of Adynovate, Takeda Pharmaceutical Co Ltd. announced the extension of its portfolio for rare diseases in India. Adynovate is a cutting-edge prolonged half-life recombinant Factor VIII (rFVIII) therapy for hemophilia A patients that make use of proven technology.

𝐊𝐞𝐲 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐑𝐚𝐫𝐞 𝐇𝐞𝐦𝐨𝐩𝐡𝐢𝐥𝐢𝐚 𝐅𝐚𝐜𝐭𝐨𝐫𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

By Type :

Factor I
Factor II
Factor V
Factor VII
Factor X
Factor XI
Factor XIII
By Application :
Fresh Frozen Plasma
Factor Concentrates
Cryoprecipitate
Others

By Region :

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

𝐌𝐨𝐫𝐞 𝐕𝐚𝐥𝐮𝐚𝐛𝐥𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐨𝐧 𝐎𝐟𝐟𝐞𝐫

Fact.MR, in its new offering, presents an unbiased analysis of the global rare hemophilia factors market, presenting historical demand data (2017-2021) and forecast statistics for the period of 2022-2032.

The study divulges essential insights on the market on the basis of type (factor I, factor II, factor V, factor VII, factor X, factor XI, factor XIII) and application (fresh frozen plasma, factor concentrates, cryoprecipitate, others), across five major regions (North America, Europe, Asia Pacific, Latin America, and MEA).

𝐊𝐞𝐲 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐌𝐮𝐬𝐜𝐥𝐞 𝐒𝐭𝐢𝐦𝐮𝐥𝐚𝐭𝐨𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭

What is the projected value of the rare hemophilia factors Industry in 2022?
At what rate will the global rare hemophilia factors market size grow until 2032?
Which are the factors hampering the growth of rare hemophilia factors?
Which region is expected to lead in the global rare hemophilia factors market By 2032?
Which are the factors driving the rare hemophilia factors Industry during the forecast period?
What is the expected market value of the rare hemophilia factors market during the forecast period?

Contact:

Us Sales Office :
11140 Rockville Pike
Suite 400
Rockville, Md 20852
United States
Tel: +1 (628) 251-1583

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range - from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories.

This release was published on openPR.